From the ground up: Launching <scp>GENETECA</scp> ™ ( <scp>GENetic</scp> education and <scp>TEsting</scp> for <scp>CAncer</scp> ) a point‐of‐care cancer genetics service at an academic medical center

In 2020, the UCLA Cancer Genetics service launched a point-of-care pilot program called GENETECA™ (GENetic Education and TEsting for CAncer) in the Pancreatic Cancer Integrated Practice Unit (PancIPU) to comply with national guidelines recommending universal germline genetic testing (gGT). We present a guide for the implementation of similar models at other institutions along with the uptake and outcomes of GENETECA. Patients with pancreatic ductal adenocarcinoma (PDAC) obtaining care at UCLA Health between August 12, 2020 and January 1, 2023 were identified through electronic medical record review. Abstracted data included patient demographics and GENETECA endpoints (gGT, opted for traditional genetic counseling visit, declined, or loss to follow up). Data were analyzed using Chi-squared testing for categorical variables and Wilcoxon rank-sum tests for non-parametric data. In 2019, prior to the implementation of GENETECA, only 9% (18/194) of patients with PDAC seen at PancIPU had pre-test counseling and gGT by cancer genetic counselors. After the implementation of GENETECA, 94% (222 out of 237) of PDAC patients were offered gGT. Approximately 80% of patients with PDAC who were offered GENETECA proceeded with testing, independent of patient age. Non-English speakers were no less likely to complete GENETECA than English-speaking patients, and no significant difference in completion was observed across races. Implementing this point-of-care, high-throughput approach significantly improved compliance with national guidelines and proved to be a cost-effective service delivery model. Its success has allowed us to procure additional financial and health system support to expand cancer genetic services across many other tumor-site specialty clinics. Our described implementation may be used as a framework for other institutions to implement similar models.

Authors

Institutions

Publication Details

Journal
Journal of Genetic Counseling
Published
2025-11-28
DOI
https://doi.org/10.1002/jgc4.70143
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From the ground up: Launching GENETECA ™ ( GENetic education and TEsting for CAncer ) a point‐of‐care cancer genetics service at an academic medical center

Mehrnaz Siavoshi, Timothy F. Donahue, Lorna C. Kwan, Daniella Kamara et al.
Journal of Genetic Counseling
BRCA gene mutations in cancer
article

From the ground up: Launching GENETECA ™ ( GENetic education and TEsting for CAncer ) a point‐of‐care cancer genetics service at an academic medical center

Mehrnaz Siavoshi, Timothy F. Donahue, Lorna C. Kwan, Daniella Kamara, Wendy Conlon, Jenny Lester, S Bedford, Beth Y. Karlan, Aletta Deranteriassian, Mariana Niell Swiller, Ramil T. Badana
article en

Abstract

In 2020, the UCLA Cancer Genetics service launched a point-of-care pilot program called GENETECA™ (GENetic Education and TEsting for CAncer) in the Pancreatic Cancer Integrated Practice Unit (PancIPU) to comply with national guidelines recommending universal germline genetic testing (gGT). We present a guide for the implementation of similar models at other institutions along with the uptake and outcomes of GENETECA. Patients with pancreatic ductal adenocarcinoma (PDAC) obtaining care at UCLA Health between August 12, 2020 and January 1, 2023 were identified through electronic medical record review. Abstracted data included patient demographics and GENETECA endpoints (gGT, opted for traditional genetic counseling visit, declined, or loss to follow up). Data were analyzed using Chi-squared testing for categorical variables and Wilcoxon rank-sum tests for non-parametric data. In 2019, prior to the implementation of GENETECA, only 9% (18/194) of patients with PDAC seen at PancIPU had pre-test counseling and gGT by cancer genetic counselors. After the implementation of GENETECA, 94% (222 out of 237) of PDAC patients were offered gGT. Approximately 80% of patients with PDAC who were offered GENETECA proceeded with testing, independent of patient age. Non-English speakers were no less likely to complete GENETECA than English-speaking patients, and no significant difference in completion was observed across races. Implementing this point-of-care, high-throughput approach significantly improved compliance with national guidelines and proved to be a cost-effective service delivery model. Its success has allowed us to procure additional financial and health system support to expand cancer genetic services across many other tumor-site specialty clinics. Our described implementation may be used as a framework for other institutions to implement similar models.

Journal of Genetic CounselingVol. 34(6)
University of California, Los Angeles (US), UCLA Health (US), USC Norris Comprehensive Cancer Center (US), Comprehensive Blood & Cancer Center (US)
Openalex Percentile: Top 61%
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.